Role of pyrimidine depletion in the mitochondrial cardiotoxicity of nucleoside analogue reverse transcriptase inhibitors

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue 5, 2010, Pages 550-557

  Balcarek, Kerstin ^a   Venhoff, Nils ^a,b   Deveaud, Catherine ^c   Beauvoit, Bertrand ^c   Bonnet, Jacques ^c   Kirschner, Janbernd ^a   Venhoff, Ana C ^a   Lebrecht, Dirk ^a   Walker, Ulrich A ^a,d  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c INSERM   (France)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

cardiomyopathy; mitochondria; oxidative phosphorylation; uridine; zidovudine

Indexed keywords

CYTOCHROME C OXIDASE; REACTIVE OXYGEN METABOLITE; URIDINE; ZALCITABINE; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOAVAILABILITY; CARDIOMYOPATHY; CELL ENLARGEMENT; CONTROLLED STUDY; COPY NUMBER VARIATION; DIET SUPPLEMENTATION; GENE MUTATION; LIPID PEROXIDATION; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PYRIMIDINE METABOLISM;

ANIMALS; ANTI-HIV AGENTS; CARDIOMYOPATHIES; CARDIOTOXINS; DIETARY SUPPLEMENTS; DNA COPY NUMBER VARIATIONS; DNA, MITOCHONDRIAL; ELECTRON TRANSPORT COMPLEX IV; HEART; HIV INFECTIONS; MICE; MICE, INBRED BALB C; MITOCHONDRIA, HEART; MUTATION; NUCLEOSIDES; PYRIMIDINES; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE INHIBITORS; URIDINE; ZALCITABINE; ZIDOVUDINE;

EID: 78650214721     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181f25946     Document Type: Article

References (43)

1. Walker UA, Bäuerle J, Laguno M, et al. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology. 2004;39:311-317.
2. Walker UA, Bickel M, Lütke Volksbeck SI, et al. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr. 2002;29:117-121.
3. Arnaudo E, Dalakas M, Shanske S, et al. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet. 1991;337:508-510.
4. Lewis W, Day BJ, Kohler JJ, et al. Decreased mtDNA, oxidative stress, cardiomyopathy, and death from transgenic cardiac targeted human mutant polymerase gamma. Lab Invest. 2007;87:326-335.
5. Lewis W, Kohler JJ, Hosseini SH, et al. Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA poly hypothesis. AIDS. 2006;20:675-684.
6. Brogly SB, Ylitalo N, Mofenson LM, et al. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS. 2007;21:929-938.
7. Frerichs FC, Dingemans KP, Brinkman K. Cardiomyopathy with mitochondrial damage associated with nucleoside reverse-transcriptase inhibitors. N Engl J Med. 2002;347:1895-1896.
8. Thoden J, Lebrecht D, Venhoff N, et al. Highly active antiretroviral HIV therapy-associated fatal lactic acidosis: quantitative and qualitative mitochondrial DNA lesions with mitochondrial dysfunction in multiple organs. AIDS. 2008;22:1093-1094.
9. Mondy K, Gottdiener J, Overton ET, et al, and SUN study investigators. Prevalence and risk factors in HIV-infected persons for echocardiographic abnormalities in the era of modern HAART. Presented at: 15th Conference on Retroviruses and Opportunistic Infections; 2008; Boston, MA. Abstract 978.
10. Dube MP, Lipshultz SE, Fichtenbaum CJ, et al. Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation. 2008; 118:e36-e40.
11. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther. 2000; 22:685-708.
12. Lynx MD, McKee EE. 3#-Azido-3#-deoxythymidine (AZT) is a competitive inhibitor of thymidine phosphorylation in isolated rat heart and liver mitochondria. Biochem Pharmacol. 2006;72:239-243.
13. Susan-Resiga D, Bentley AT, Lynx MD, et al. Zidovudine inhibits thymidine phosphorylation in the isolated perfused rat heart. Antimicrob Agents Chemother. 2007;51:1142-1149.
14. De La Asuncion JG, del Olmo ML, Sastre J, et al. AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins. J Clin Invest. 1998;102:4-9.
15. Pursell ZF, McDonald JT, Mathews CK, et al. Trace amounts of 8-oxo-dGTP in mitochondrial dNTP pools reduce DNA polymerase gamma replication fidelity. Nucleic Acids Res. 2008;36:2174-2181.
16. Gattermann N, Dadak M, Hofhaus G, et al. Severe impairment of nucleotide synthesis through inhibition of mitochondrial respiration. Nucleosides Nucleotides Nucleic Acids. 2004;23:1275-1279.
17. Setzer B, Lebrecht D, Walker UA. Pyrimidine nucleoside depletion sensitizes to the mitochondrial hepatotoxicity of the reverse transcriptase inhibitor stavudine. Am J Pathol. 2008;172:681-690.
18. Venhoff N, Zilly M, Lebrecht D, et al. Uridine pharmacokinetics of Mitocnol, a sugar cane extract. AIDS. 2005;19:739-740.
19. Note R, Maisonneuve C, Letteron P, et al. Mitochondrial and metabolic effects of nucleoside reverse transcriptase inhibitors (NRTIs) in mice receiving one of five single- and three dual-NRTI treatments. Antimicrob Agents Chemother. 2003;47:3384-3392.
20. Lebrecht D, Setzer B, Ketelsen UP, et al. Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation. 2003;108:2423-2429.
21. Frings CS, Fendley TW, Dunn RT, et al. Improved determination of total serum lipids by the sulfo-phospho-vanillin reaction. Clin Chem. 1972;18: 673-674.
22. Lebrecht D, Vargas Infante YA, Setzer B, et al. Uridine supplementation antagonizes zalcitabine-induced microvesicular steatohepatitis in mice. Hepatology. 2007;45:72-79.
23. Walker UA, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS. 2002;16:2165-2173.
24. Angel MF, Ramasastry SS, Swartz WM, et al. The critical relationship between free radicals and degrees of ischemia: evidence for tissue intolerance of marginal perfusion. Plast Reconstr Surg. 1988;81:233-239.
25. Samuels DC, Schon EA, Chinnery PF Two direct repeats cause most human mtDNA deletions. Trends Genet. 2004;20:393-398.
26. Tanhauser SM, Laipis PJ. Multiple deletions are detectable in mitochondrial DNA of aging mice. J Biol Chem. 1995;270:24769-24775.
27. Rylova SN, Albertioni F, Flygh G, et al. Activity profiles of deoxynucleo-side kinases and 5' -nucleotidases in cultured adipocytes and myoblastic cells: insights into mitochondrial toxicity of nucleoside analogs. Biochem Pharmacol. 2005;69:951-960.
28. Song S, Pursell ZF, Copeland WC, et al. DNA precursor asymmetries in mammalian tissue mitochondria and possible contribution to mutagenesis through reduced replication fidelity. Proc Natl Acad Sci USA. 2005;102: 4990-4995.
29. Corral-Debrinski M, Stepien G, Shoffner JM, et al. Hypoxemia is associated with mitochondrial DNA damage and gene induction. Implications for cardiac disease. JAMA. 1991;266:1812-1816.
30. Larsson NG, Holme E, Kristiansson B, et al. Progressive increase of the mutated mitochondrial DNA fraction in Kearns-Sayre syndrome. Pediatr Res. 1990;28:131-136.
31. Walker UA, Venhoff N, Koch E, et al. Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells. Antivir Ther. 2003;8:463-470.
32. Walker UA, Venhoff N Uridine in the prevention and treatment of NRTI-related mitochondrial toxicity. Antivir Ther. 2005;10:M117-M123.
33. Fox RI. Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol Suppl. 1998;53:20-26.
34. Lebrecht D, Deveaud C, Beauvoit B, et al. Uridine supplementation antagonizes zidovudine-induced mitochondrial myopathy and hyper-lactatemia in mice. Arthritis Rheum. 2008;58:318-326.
35. Weinberg ME, Roman MC, Jacob P, et al. Single-dose and cumulative pharmacokinetis of the food supplement NucleomaxX® and mechanism for enhanced bioavailability of uridine. Antivir. Ther. 2007;12: (Suppl 2):L25.
36. Sutinen J, Walker UA, Sevastianova K, et al. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial. Antivir Ther. 2007;12: 97-105.
37. Banasch M, Goetze O, Knyhala K, et al. Uridine supplementation enhances hepatic mitochondrial function in thymidine-analogue treated HIV-infected patients. AIDS. 2006;20:1554-1556.
38. Koch EC, Schneider J, Weiss R, et al. Uridine excess does not interfere with the antiretroviral efficacy of nucleoside analogue reverse transcrip-tase inhibitors. Antivir Ther. 2003;8:485-487.
39. McComsey GA, O#Riordan M, Setzer B, et al. Uridine supplementation in HIV lipoatrophy: pilot trial on safety and effect on mitochondrial indices. Eur J Clin Nutr. 2008;62:1031-1037.
40. Sommadossi JP, Carlisle R, Schinazi RF, et al. Uridine reverses the toxicity of 3#-azido-3#-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity. Antimicrob Agents Chemother. 1988;32:997-1001.
41. Schon EA, Rizzuto R, Moraes CT, et al. A direct repeat is a hotspot for large-scale deletion of human mitochondrial DNA. Science. 1989;244: 346-349.
42. Tsutsui H, Kinugawa S, Matsushima S. Mitochondrial oxidative stress and dysfunction in myocardial remodelling. Cardiovasc Res. 2009;81:449-456.
43. Holt IJ, Harding AE, Morgan-Hughes JA. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature. 1988;331:717-719.